PHARMACY 4.0

THE IMPORTANCE OF POLPHARMA IN BUILDING AN INNOVATIVE ECONOMY 

Polphar­ma is a leader of the Polish phar­ma­ceu­ti­cal indu­stry, a major inve­stor, an inno­va­tor and a major com­pa­ny among the top twen­ty gene­ric manu­fac­tu­rers in the world.

In this report we ana­ly­ze what is the reason for its undo­ub­ted suc­cess and how it trans­la­tes into the deve­lop­ment of the Polish eco­no­my. We also point out the most impor­tant chal­len­ges facing Polphar­ma and the Polish phar­ma­ceu­ti­cal sector.

Sha­re

Sha­re on facebook
Sha­re on twitter
Sha­re on linkedin
Sha­re on pinterest
Sha­re on email

POLPHARMA IN FIGURES 

Grafika poglądowa

MORE THAN 7,000 EMPLOYEES WORLDWIDE

PRESENT IN 60 GLOBAL MARKETS

Grafika poglądowa

THE 20TH LARGEST GENERIC COMPANY IN THE WORLD

Grafika poglądowa

64 ACTIVE PATENTS

Grafika poglądowa

OVER 600 MOLECULES IN PORTFOLIO

Grafika poglądowa

41 DRUGS WITHOUT AN EQUIVALENT

INVESTMENTS IN THE DEVELOPMENT OF BIOLOGIC DRUG PRODUCTION AND MANUFACTURING TECHNOLOGIES

Inve­st­ments in bio­tech­no­lo­gies are nowa­days con­si­de­red to be one of the most pro­mi­sing direc­tions of deve­lop­ment in the phar­ma­ceu­ti­cal sector:

  • sin­ce 2012, Polphar­ma Gro­up’s spen­ding on its bio­tech divi­sion has been gro­wing steadily,
  • Polphar­ma plans to beco­me the only pro­du­cer and manu­fac­tu­rer of bio­lo­gi­cal drugs in Poland by inve­sting in a pro­duc­tion plant in Duch­ni­ce (plan­ned start-up in 2019, inve­st­ment value PLN 451.5 mil­lion) and a sta­te-of-the-art labo­ra­to­ry in Gdansk (inve­st­ment value PLN 224.7 million)
  • The Gro­up took over the inno­va­ti­ve Dutch bio­tech­no­lo­gy com­pa­ny Bio­ce­ros, thus empha­si­zing its role in the still too small gro­up of Polish com­pa­nies inve­sting abroad

POLPHARMA’S EXPENDITURE ON BIOTECHNOLOGY RELATED R&D (PLN M)

Sour­ce: Polphar­ma Gro­up inter­nal data.

At Polpharma, spending on research in the area of biotechnology is growing exponentially: in 2016 it amounted to over PLN 200 million.

R&D EXPENDITURE IN THE POLISH PHARMACEUTICAL SECTOR (PLN M)

Wykres objaśniający

POLPHARMA’S EXPENDITURE ON BIOTECHNOLOGY RELATED R&D (PLN M)

Sour­ce: Polphar­ma Gro­up inter­nal data.

DEVELOPMENT OF AN EXTENSIVE PATENT PORTFOLIO

Polphar­ma­’s patent port­fo­lio deve­lop­ment includes:

  • sub­stan­ces(Polphar­ma has deve­lo­ped new methods of obta­ining a num­ber of the­ra­peu­tic acti­ve substances)
  • drug forms (in the case of many wide­ly used drugs, Polphar­ma mana­ged to chan­ge the form of admi­ni­stra­tion or eli­mi­na­te harm­ful pre­se­rva­ti­ves, thus impro­ving the quali­ty of patient treatment)
  • bio­tech­no­lo­gi­cal inno­va­tions (despi­te only a few years of invo­lve­ment in the deve­lop­ment of Polphar­ma­’s bio­tech­no­lo­gy divi­sion, the com­pa­ny has mana­ged to obta­in seve­ral patents for both the deve­lop­ment of new cell lines and new agents used in the pro­duc­tion of bio­lo­gi­cal substances)

PATENTS GRANTED TO POLPHARMA GROUP FOR ACTIVE SUBSTANCES IN 1999–2016

Sour­ce: Polphar­ma Gro­up inter­nal data.

Polpharma is not an occasional innovator. Successively growing expenditure on R&D (between 2012 and 2015 it accounted for more than 50% of the total pharmaceuticals sector expenditure in Poland for this purpose) is systematically translated into new patent applications.

CHANGES GUIDING POLPHARMA TOWARDS PHARMA 4.0.

  • Polphar­ma is one of the few Polish com­pa­nies to imple­ment new tech­no­lo­gies on a lar­ge sca­le, which makes it a pio­ne­er in the field of so-cal­led Indu­stry 4.0, i.e. a new way of orga­ni­sing pro­duc­tion and com­pa­ny ope­ra­tions resul­ting from bro­ad inte­gra­tion of a varie­ty of com­pu­ter-con­trol­led processes
  • Inte­gra­tion and fur­ther auto­ma­tion of orga­ni­za­tio­nal and pro­duc­tion pro­ces­ses in Polphar­ma inc­lu­des mana­ge­ment of buil­dings, pro­duc­tion, human reso­ur­ces, logi­stics, docu­ment flow, data visu­ali­za­tion and pro­ces­sing as well as com­mu­ni­ca­tion with subcontractors

CURRENT IMPLEMENTATIONS OF INDUSTRY 4.0 USED IN POLPHARMA GROUP

STRATEGIC INVESTMENTS IN HUMAN CAPITAL 

  • Polphar­ma Gro­up acco­unts for 16% of all employ­ees in the Polish phar­ma­ceu­ti­cal industry,
  • Sala­ries here are on ave­ra­ge 12% higher than tho­se of competitors,
  • The pro­por­tion of R&D staff in the Polphar­ma Gro­up cle­ar­ly exce­eds that of the Polish phar­ma­ceu­ti­cal indu­stry and the­ir sala­ries are on ave­ra­ge 50% higher than tho­se of the competition,
  • Polphar­ma acti­ve­ly coun­te­racts the out­flow of high­ly quali­fied work­for­ce by con­duc­ting return pro­gram­mes for Polish bio­tech­no­lo­gi­sts and che­mi­sts employ­ed by Western Euro­pe­an companies
  • It also pro­mo­tes the return of aban­do­ned coope­ra­tion with edu­ca­tio­nal insti­tu­tions by co-run­ning dual clas­ses at the tech­ni­cal scho­ol level and bio­me­di­cal facul­ties at the uni­ver­si­ty level

MONTHLY REMUNERATION IN THE POLPHARMA GROUP COMPARED TO THE PHARMACEUTICAL SECTOR

Sour­ce: Polphar­ma Gro­up’s inter­nal data and the Cen­tral Sta­ti­sti­cal Offi­ce (GUS).

Every 7th employee in the pharmaceutical sector is employed by Polpharma Group.

CONSISTENT FOREIGN EXPANSION 

  • Polphar­ma Gro­up has a posi­ti­ve fore­ign tra­de balan­ce and the value of exports exce­eds the value of imports, which gives the com­pa­ny an excep­tio­nal sta­tus com­pa­red to other phar­ma­ceu­ti­cal companies
  • Polphar­ma adopts direct inve­st­ment stra­te­gies in high-poten­tial mar­kets such as Rus­sia and Kaza­kh­stan, whe­re it sup­ports acqu­isi­tions and mer­gers with local part­ners and has its own drug pro­duc­tion faci­li­ties From the­se coun­tries it exports drugs to tra­di­tio­nal­ly tra­de-lin­ked neigh­bo­uring countries
  • In smal­ler deve­lo­ping mar­kets Polphar­ma adopts a sales deve­lop­ment stra­te­gy based on its own sales offi­ces or local distri­bu­tors of drugs expor­ted from Poland. It is pre­sent in all glo­bal mar­kets, in a total of 60 coun­tries – either as a drug manu­fac­tu­rer, acti­ve ingre­dient sup­plier or a com­pa­ny that licen­ses its products

PHARMACEUTICAL SECTOR TRADE BALANCE IN 2016

Sour­ce: Own ana­ly­sis based on data from PZPPF and busi­ness intel­li­gen­ce agen­cies: Bisno­de and Infocredit.

POLPHARMA DRUGS WITH LARGEST SHARE OF SALES VOLUME, 2015, MILLION UNITS

Wykres objaśniający

Sour­ce: Polphar­ma Gro­up inter­nal data.

MATERIAL STRUCTURE OF POLPHARMA’S EXPORTS IN 2015
(IN PLN M)

Sour­ce: Polphar­ma Gro­up inter­nal data.

Over 90% of Polpharma’s exports are compounded and unblended drugs. 

IMPACT ON THE COUNTRY’S DRUG SECURITY 

  • Polphar­ma as a dome­stic manu­fac­tu­rer of drugs and acti­ve sub­stan­ces pro­vi­des access to tre­at­ment for a wide ran­ge of patients in case of une­xpec­ted events (public health cri­ses, eco­no­mic down­turn, etc.).
  • Thanks to gene­ric pro­duc­tion, the pri­ces of drugs pre­vio­usly cove­red by pro­tec­tion (so-cal­led ori­gi­nal drugs) are redu­ced by 80%, which allows for a signi­fi­cant bro­ade­ning of the gro­up of patients cove­red by therapy

THERAPEUTIC GROUPS IN WHICH POLPHARMA IS THE SALES LEADER (%)

Sour­ce: Polphar­ma Gro­up inter­nal data.

SUPPLY OF REIMBURSED DRUGS IN 2016. (TOP 10 COMPANIES) 

Wykres objaśniający

Sour­ce: NFZ.

From the perspective of the country’s drug security, it is incomparably more important to support access to cheap and effective drugs for hypertension, which affects one in four Poles, than to stimulate investment in the development of new treatments for rare diseases.

Authors of the report

Zdjęcie jednego z autorów raportu
dr. Jacek Lewkowicz
Zdjęcie jednego z autorów raportu
Jakub Janiszewski
Scroll to Top